GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (FRA:CY3) » Definitions » Shiller PE Ratio

DMK Pharmaceuticals (FRA:CY3) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is DMK Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


DMK Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for DMK Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Shiller PE Ratio Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DMK Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Shiller PE Ratio falls into.



DMK Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

DMK Pharmaceuticals's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, DMK Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.187/129.8595*129.8595
=-0.187

Current CPI (Sep. 2023) = 129.8595.

DMK Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -41.902 98.326 -55.340
201403 -9.110 99.695 -11.866
201406 -13.910 100.560 -17.963
201409 -10.864 100.428 -14.048
201412 -23.276 99.070 -30.510
201503 -20.698 99.621 -26.981
201506 -16.840 100.684 -21.720
201509 -14.969 100.392 -19.363
201512 -17.350 99.792 -22.577
201603 -30.173 100.470 -38.999
201606 -23.051 101.688 -29.437
201609 -25.572 101.861 -32.601
201612 3.982 101.863 5.076
201703 -17.017 102.862 -21.483
201706 -11.837 103.349 -14.873
201709 -12.333 104.136 -15.380
201712 -14.196 104.011 -17.724
201803 -13.057 105.290 -16.104
201806 -17.377 106.317 -21.225
201809 -12.598 106.507 -15.360
201812 -17.228 105.998 -21.106
201903 -11.771 107.251 -14.252
201906 -9.912 108.070 -11.911
201909 -7.627 108.329 -9.143
201912 -3.150 108.420 -3.773
202003 -6.968 108.902 -8.309
202006 -11.189 108.767 -13.359
202009 -8.915 109.815 -10.542
202012 -11.508 109.897 -13.598
202103 -7.056 111.754 -8.199
202106 -3.486 114.631 -3.949
202109 -4.760 115.734 -5.341
202112 -3.717 117.630 -4.103
202203 -4.449 121.301 -4.763
202206 -3.708 125.017 -3.852
202209 -2.071 125.227 -2.148
202212 -1.680 125.222 -1.742
202303 -3.923 127.348 -4.000
202306 -3.138 128.729 -3.166
202309 -0.187 129.860 -0.187

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DMK Pharmaceuticals  (FRA:CY3) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


DMK Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (FRA:CY3) Business Description

Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (FRA:CY3) Headlines

No Headlines